• SenzaGen swung to its first quarterly operating profit of SEK 1.1 million in Q3 2026.
• Net sales rose 7% year-over-year to SEK 16.3 million.
• January-September operating loss narrowed 59% to SEK 3.1 million, while net sales climbed 10% to SEK 46.5 million year-over-year.
• Following the reporting period, SenzaGen agreed to acquire Alcyomics, a profitable UK provider of non-animal immunotoxicology testing for drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SenzaGen AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.